Skip to main content
SpringerLink
Log in

Tamoxifen alone versus tamoxifen plus 1-(2-tetrahydrofuryl)-5-fluorouracil in the treatment of advanced breast cancer: A sequential trial

  • US-Japan Conference on Chemoendocrine Therapy
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

During the past 4 years, a sequential study was conducted to compare the effect of tamoxifen (TAM) alone and TAM plus 1-(2-tetrahydrofuryl)-5-fluorouracil (FT) in the treatment of advanced breast cancer. The overall response rates were 28.9% in 45 patients treated with TAM, and 43.2% in 37 treated with TAM + FT. In regard to dominant site of lesions, 4 out of 9 patients (44.4%) with visceral involvement responded to TAM + FT, whereas none out of 10 responded to TAM alone. In a crossover study, 4 out of 5 failures to TAM responded favorably to TAM + FT. The median value of survival was 24 months in patients treated with TAM alone and 36 months with TAM + FT. Side effects such as gastrointestinal disorders and bone marrow suppression slightly increased in incidence when cytotoxic chemotherapy was combined with TAM. The present chemo-endocrine regimen with TAM + FT showed some advantages over TAM alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cole MP, Jones CTA, Todd IDH: A new anti-oestrogenic agent in late breast cancer: An early clinical appraisal of ICI46474. Brit J Cancer 25: 270–275, 1971.

    PubMed  Google Scholar 

  2. Mouridsen H, Palshof T, Patterson J, Battersby L: Tamoxifen in advanced breast cancer. Cancer Treat Rev 5: 131–141, 1978.

    PubMed  Google Scholar 

  3. Morgan LR Jr, Schein PS, Woolley PV, Hoth D, Macdonald J, Lippman M, Posey LE, Beazley RW: Therapeutic use of tamoxifen in advanced breast cancer: Correlation with biochemical parameters. Cancer Treat Rep 60: 1437–1443, 1976.

    PubMed  Google Scholar 

  4. Lerner HJ, Band PR, Israel L, Leung BS: Phase II study of tamoxifen: Report of 74 patients with stage IV breast cancer. Cancer Treat Rep 60: 1431–1435, 1976.

    PubMed  Google Scholar 

  5. Leclercq G, Heuson JC, Deboel MC, Mattheiem WH: Oestrogen receptors in breast cancer: A changing concept. Brit Med J 1: 185–189, 1975.

    PubMed  Google Scholar 

  6. Mercer WD, Carlson CA, Wahl TM, Teague PO: Identification of estrogen receptors in mammary cancer cells by immunofluorescence. Am J Clin Path 70: 330, 1978.

    Google Scholar 

  7. Tormey DC, Falkson H, Falkson G, Davis TE: Evaluation of chemotherapy + tamoxifen in breast cancer (abstr). Proc AACR and ASCO 19: 34, 1978.

    Google Scholar 

  8. Glick J, Creech RH, Torri S, Holroyde C, Brodovsky H, Catalano RB, Varano M: Tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal patients with advanced breast cancer: A randomized trial. Cancer 45: 735–741, 1980.

    PubMed  Google Scholar 

  9. Ahmann DL, O'Connell MJ, Hahn RG, Bisel HF, Lee RA, Edmonson JH: An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy. N Engl J Med 297: 356–360, 1977.

    PubMed  Google Scholar 

  10. Brunner KW, Sonntag RW, Alberto P, Senn HJ, Martz G, Obrecht P, Maurice P: Combined chemo- and hormonal therapy in advanced breast cancer. Cancer 39: 2923–2933, 1977.

    PubMed  Google Scholar 

  11. Oberfield RA, Cady B, Pazianos AG, Salzman FA: Adrenalectomy-oophorectomy and combined chemotherapy for carcinoma of the breast with metastases. Surg Gynecol Obstet 148: 881–886, 1979.

    PubMed  Google Scholar 

  12. Wada T, Koyama H, Terasawa T: Recent advances in chemotherapy for advanced breast cancer. Recent Results in Cancer Research, in press.

  13. Karev NI, Blokhina NG, Vozny EK, Pershin MP: Experience with ftorafur treatment in breast cancer. Neoplasma 19: 347–350, 1972.

    PubMed  Google Scholar 

  14. Konda C, Niitani H, Sakauchi N, Suzuki A, Sakai Y, Sakano T, Shimoyama M, Kitahara T, Kumaoka S, Kimura K: Chemotherapy of cancer with oral administration of N1-(2′-furanidyl)-5-fluorouracil. Jap J Cancer Clin 19: 495–499, 1973.

    Google Scholar 

  15. Takemasa Y, Suehara M, Koyama Y, Kimura T: Evaluation of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) in solid tumors. Cancer and Chemotherapy 1: 259–265, 1974.

    Google Scholar 

  16. Wada T, Koyama H, Terasawa T: Effect of tamoxifen in premenopausal Japanese women with advanced breast cancer. Cancer Treat Rep 65, 1981, in press.

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, The Center for Adult Diseases, Osaka, Japan

    Tomio Wada M.D., Hiroki Koyama M.D. & Toshio Terasawa M.D.

Authors
  1. Tomio Wada M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroki Koyama M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Toshio Terasawa M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Address for reprints: Tomio Wada, M.D., Dept. of Surgery, The Center for Adult Diseases, Osaka, 1-3-3, Nakamichi, Higashinari-ku, Osaka 537, Japan

Head of the Department.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wada, T., Koyama, H. & Terasawa, T. Tamoxifen alone versus tamoxifen plus 1-(2-tetrahydrofuryl)-5-fluorouracil in the treatment of advanced breast cancer: A sequential trial. Breast Cancer Res Tr 1, 53–58 (1981). https://doi.org/10.1007/BF01807892

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01807892

Keywords

Search

Navigation